Transcranial Electrical Stimulation Targeting the Cerebellum for the Treatment of Refractory Temp… (NCT06558890) | Clinical Trial Compass
UnknownNot Applicable
Transcranial Electrical Stimulation Targeting the Cerebellum for the Treatment of Refractory Temporal Lobe Epilepsy
China60 participantsStarted 2024-06-08
Plain-language summary
Study the therapeutic effect and potential neural mechanisms of transcranial electrical stimulation targeting the cerebellum for the treatment of refractory temporal lobe epilepsy through MRI and EEG.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 and 65 years old;
✓. Diagnosed with refractory temporal lobe epilepsy as defined by the International League Against Epilepsy (ILAE) (failure to achieve seizure-free status after adequate trials of two appropriate antiepileptic drugs);
✓. Duration of epilepsy is at least 2 years, with a seizure frequency of at least 2 times per 4 weeks in the three months before enrollment;
✓. Taking two or more antiepileptic drugs, and continuing the same medication treatment plan during the trial period;
✓. Capable of cooperating to complete the treatment and related examination items;
✓. The patient and family members fully understand and voluntarily sign the informed consent form.
Exclusion criteria
✕. Scalp skin damage (including skin diseases or damage in the area where electrodes are applied);
✕. Psychogenic epilepsy or pseudo-epilepsy;
✕. Concurrent severe infections, cerebrovascular diseases, malignant tumors, or other diseases with severe dysfunction of major organs such as the heart, liver, and kidneys, or with mental disorders;
✕. Presence of any implanted devices or instruments (such as cardiac pacemakers, deep brain stimulators, cochlear implants, and vagus nerve stimulators, etc.);
✕. History of head trauma or other brain-related diseases;
What they're measuring
1
Compared to baseline, the reduction rate of epileptic seizure frequency
Timeframe: baseline, 10 weeks,14 weeks after treatment